Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Bruker Reaches Analyst Target Price
Thursday, February 9, 8:45 AM ET, by Market News Video Staff

In recent trading, shares of Bruker Corp (BRKR) have crossed above the average analyst 12-month ...

Innoviva (INVA) Shares Cross Above 200 DMA
Thursday, February 9, 11:47 AM ET, by Market News Video Staff

In trading on Thursday, shares of Innoviva Inc (INVA) crossed above their 200 day moving ...

Noteworthy Thursday Option Activity: BRKR, X, KPTI
Thursday, February 9, 3:34 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Bullish Two Hundred Day Moving Average Cross - LXRX
Friday, February 10, 11:37 AM ET, by Market News Video Staff

In trading on Friday, shares of Lexicon Pharmaceuticals, Inc. (LXRX) crossed above their 200 day ...

We Did The Math PBE Can Go To $52
Thursday, February 16, 8:27 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

  More articles:  1 2 3 4 5 6 7 next »

Bruker Corp Breaks Below 200-Day Moving Average - Notable for BRKR

By Market News Video Staff, Thursday, November 29, 12:17 PM ET
Play Video: Learn About The 200 DMA

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Thursday, shares of Bruker Corp (NASDAQ:BRKR) crossed below their 200 day moving average of $13.96, changing hands as low as $13.88 per share. Bruker Corp shares are currently trading up about 1% on the day. The chart below shows the one year performance of BRKR shares, versus its 200 day moving average:

Bruker Corp 200 Day Moving Average Chart

Looking at the chart above, BRKR's low point in its 52 week range is $9.91 per share, with $17.10 as the 52 week high point that compares with a last trade of $14.55.

Special Offer: Manage the risks of the markets better with a free 30 day trial to the Strategic Risk Management System.

According to the ETF Finder at ETF Channel, BRKR makes up 3.32% of the Dynamic Biotechnology & Genome Portfolio ETF (AMEX:PBE) which is trading up by about 0.9% on the day Thursday.

See what other ETFs contain BRKR
See what other stocks are held by PBE

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   AMEX   According   BRKR   Biotechnology   Bruker   Corp   Crossing   ETFs   Finder   Genome   Looking   Management   Risk   Special   Start   Stocks   Strategic   System   Their   Thursday   about   average   below   better   changing   chart   compares   currently   hands   held   last   makes   markets   moving   other   point   range   raquo   share   shares   slideshow   that   trading   trial   versus   week   what   which   with   year
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Portfolio Channel Stock Market Definitions

Bruker Corp Breaks Below 200-Day Moving Average - Notable for BRKR | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.